Bookmark

Add to MyYahoo RSS

ZIOPHARM Oncology News

News on ZIOPHARM Oncology (Ticker: ZIOP) continually updated from thousands of sources around the net.

Friday Aug 8 | BioSpace

ZIOPHARM, Inc. Reports Second-Quarter 2014 Financial Results And Reviews Recent Activities

ZIOPHARM Oncology, Inc. today announced financial results for the second quarter ended June 30, 2014, and provided an update on the company's product development activities.

Comment?

Related Topix: Startups, Zio, Biotech, Oncology, Medicine, Cancer

Thu Aug 07, 2014

AmericanBankingNews.com

ZIOPHARM Oncology (ZIOP) Releases Quarterly Earnings Results

ZIOPHARM Oncology posted its quarterly earnings results on Thursday. The company reported earnings per share for the quarter, beating the analysts' consensus estimate of by $0.11, Analyst Ratings Network.com reports.

Comment?

Related Topix: Biotech, Startups, Oncology, Medicine, Zio

Sys-Con Media

Biotech Equities Technical Analysis -- BioMarin Pharma, Merrimack...

However the gains were not broad based as six out of ten sectors ended the session in negative.

Comment?

Related Topix: Startups, BioMarin Pharmaceutical, Sangamo Biosciences, Biotech, Medicine, Dyax, Healthcare Industry, Bind Biosciences, Zio

Fri Aug 01, 2014

BioSpace

ZIOPHARM Oncology, Inc. And Solasia Pharma K.K. Announce Global...

ZIOPHARM Oncology, Inc. , a biopharmaceutical company focused on the development and commercialization of new cancer therapies, and Solasia Pharma K.K. , a developer of oncology pharmaceuticals in-licensed for commercialization in major markets throughout the world, announced today an amendment and restatement of their License and Collaboration ... (more)

Comment?

Related Topix: Oncology, Medicine, Startups, Zio, Biotech, Cancer, Health, South Korea, World News, Asia, Lymphoma

Tue Jul 22, 2014

BioSpace

ZIOPHARM, Inc. Announces Expansion Of Ground-Breaking Synthetic...

ZIOPHARM Oncology, Inc. , a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon Corporation to include chimeric antigen receptor T-cell therapy.

Comment?

Related Topix: Biotech, Startups, Zio, Oncology, Medicine, Biology, Science, Immunology

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••